資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34428
|
| 標題: | Plasma Extracellular Vesicle alpha-Synuclein Level in Patients with Parkinson's Disease |
| 作者: | Chung, Chen-Chih
Chan, Lung
Chen, Jia-Hung
Hung, Yi-Chieh
Hong, Chien-Tai |
| 貢獻者: | Taipei Med Univ, Dept Neurol, Shuang Ho Hosp
Taipei Med Univ, Sch Med, Dept Neurol, Coll Med
Taipei Med Univ, Grad Inst Biomed Informat
Chi Mei Med Ctr, Dept Neurosurg, Dept Surg
Chia Nan Univ Pharm & Sci, Dept Recreat & Healthcare Management |
| 關鍵字: | extracellular vesicles
Parkinson's disease
akinetic-rigidity
alpha-synuclein |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:52:13 (UTC+8) |
| 出版者: | MDPI |
| 摘要: | Background: The most established pathognomonic protein of Parkinson's disease (PD), alpha-synuclein, is extensively investigated for disease diagnosis and prognosis; however, investigations into whether the free form of alpha-synuclein in the blood functions as a PD biomarker have not been fruitful. Extracellular vesicles (EVs) secreted from cells and present in blood transport molecules are novel platforms for biomarker identification. In blood EVs, alpha-synuclein originates predominantly from the brain without the interference of the blood-brain barrier. The present study investigated the role of plasma EV-borne alpha-synuclein as a biomarker of PD. Methods: Patients with mild to moderate stages of PD (n = 116) and individuals without PD (n = 46) were recruited to serve as the PD study group and the control group, respectively. Plasma EVs were isolated, and immunomagnetic reduction-based immunoassay was used to assess EV alpha-synuclein levels. Conventional statistical analysis was performed using SPSS 25.0, and p < 0.05 was considered significant. Results: Compared with controls, we observed significantly lower plasma EV alpha-synuclein levels in the patients with PD (PD: 56.0 +/- 3.7 fg/mL vs. control: 74.5 +/- 4.3 fg/mL, p = 0.009), and the significance remained after adjustment for age and sex. Plasma EV alpha-synuclein levels in the patients with PD did not correlate with age, disease duration, Part I and II scores of the Unified Parkinson's Disease Rating Scale (UPDRS), or the Mini-Mental State Examination scores. However, such levels were significantly correlated with UPDRS Part III score, which assesses motor dysfunction. Furthermore, the severity of akinetic-rigidity symptoms, but not tremor, was inversely associated with plasma EV alpha-synuclein level. Conclusion: Plasma EV alpha-synuclein was significantly different between the control and PD group and was associated with akinetic-rigidity symptom severity in patients with PD. This study corroborates the possible diagnostic and subtyping roles of plasma EV alpha-synuclein in patients with PD, and it further provides a basis for this protein's clinical relevance and feasibility as a PD biomarker. |
| 關聯: | BIOMOLECULES, v.11, n.5 |
| 顯示於類別: | [休閒保健管理系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| biom11050744.pdf | | 999Kb | Adobe PDF | 79 | 檢視/開啟 | | index.html | | 0Kb | HTML | 286 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
